The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark

Danish Medical Bulletin

Volumn 49, Issue 4, 2002, Pages 318-345

  Jensen, Henrik Kjœrulf ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR;

CLINICAL FEATURE; DENMARK; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; FRAMESHIFT MUTATION; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MISSENSE MUTATION; MOLECULAR GENETICS; NONSENSE MUTATION; PATHOGENESIS; PATHOGENICITY; PREVALENCE; RECEPTOR GENE; REVIEW; RNA SPLICING;

APOLIPOPROTEINS; CHOLESTEROL, LDL; CORONARY DISEASE; DENMARK; GENOTYPE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MOLECULAR BIOLOGY; RECEPTORS, LIPOPROTEIN; RISK FACTORS; VARIATION (GENETICS);

EID: 0036860336     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (434)

1. Jensen HK, Jensen LG, Hansen PS, Faergeman O, Gregersen N. High sensitivity of the single-strand conformation polymorphism method for detection of sequence variations in the low-density lipoprotein receptor gene validated by DNA sequencing. Clinical Chemistry 1996; 42: 1140-1146.
2. Jensen HK, Jensen LG, Heath F, Melsen F, Hansen PS, Meinertz H, Bolund L, Gregersen N, Færgeman O. Phenotypic characterization of a patient homozygous for the D558N LDL receptor gene mutation. Clinical Genetics 1996; 50: 388-392.
3. Jensen HK, Jensen LG, Holst HU, Andreasen PH, Hansen PS, Larsen ML, Kølvraa S, Bolund L, Gregersen N, Færgeman O. Normolipidemia and hypercholesterolemia in persons heterozygous for the same 1592+5G→A splice site mutations in the low-density lipoprotein receptor gene. Clinical Genetics 1999; 56: 378-388.
4. Jensen HK, Jensen LG, Meinertz H, Hansen PS, Gregersen N, Færgeman O. Spectrum of LDL receptor gene mutations in Denmark: Implications for molecular diagnostic strategy in heterozygous familial hypercholesterolemia. Atherosclerosis 1999; 146: 337-344.
5. 66-Gly mutations of the LDL receptor gene: Common causes of familial hypercholesterolemia in Denmark. Atherosclerosis 1996; 120: 57-65.
6. Jensen HK, Holst H, Jensen LG, Jørgensen MM, Andreasen PH, Jensen TG, Andresen BS, Heath F, Hansen PS, Neve S, Kristiansen K, Færgeman O, Kølvraa S, Bolund L, Gregersen N. A common W556S mutation in the LDL receptor gene of Danish patients with familial hypercholesterolemia encodes a transport-defective protein. Atherosclerosis 1997; 131: 67-72.
7. Jensen HK, Jensen LG, Hansen PS, Færgeman O, Gregersen N. Two point mutations (313+1G→A and 313+1G→T) in the splice donor site of intron 3 of the low-density lipoprotein receptor gene are associated with familial hypercholesterolemia. Human Mutation 1996; 7: 269-271.
8. -1-to-A acceptor splice site LDLR mutant allele leads to reduced relative transcript levels in patients with heterozygous familial hypercholesterolemia. Clinical Genetics 1996; 49: 175-179.
9. Jensen HK, Hansen PS, Jensen LG, Kristensen MJ, Klausen IC, Kjeldsen M, Lemming L, Bolund L, Gregersen N, Færgeman O. Complexity of molecular genetics of dyslipidemia in a family highly susceptible to ischemic heart disease. Clinical Genetics 1995; 48: 23-28.
10. Jensen HK, Jensen TG, Færgeman O, Jensen LG, Andresen BS, Corydon MJ, Andreasen PH, Hansen PS, Heath F, Bolund L, Gregersen N. Two mutations in the same low-density lipoprotein receptor allele act in synergy to reduce receptor function in heterozygous familial hypercholesterolemia. Human Mutation 1997; 9: 437-444.
11. Aalto-Setälä K, Gylling H, Helve E, Kovanen P, Miettinen TA, Turtola H, Kontula K. Genetic polymorphism of the apolipoprotein B gene locus influences serum LDL cholesterol level in familial hypercholesterolemia. Hum Genet 1989; 82: 305-307.
12. Adlersberg D, Parets AD, Boas EP. Genetics of atherosclerosis. Studies of families with xanthoma and unselected patients with coronary artery disease under the age of fifty years. JAMA 1949; 141: 246-254.
13. Agatson AS, Janowitz WR, Kaplan G, Gasso J, Hildner F, Viamonte M Jr. Ultrafast computed tomography-detected coronary calcium reflects the angiographic extent of coronary arterial atherosclerosis. Am J Cardiol 1994; 74: 1272-1274.
14. Alvord RM. Coronary heart disease and xanthoma tuberosum associated with hereditary hyperlipidemia. Arch Intern Med 1949; 84: 1002-1019.
15. Andersen GE, Friis-Hansen B. Neonatal diagnosis of familial type II hyperlipoproteinemia. Pediatrics 1976; 214-220.
16. Andersen GE, Lous P, Friis-Hansen B. Screening for hyperlipoproteinemia in 10000 danish newborns. Follow-up studies in 522 children with elevated chord serum VLDL-LDL-Cholesterol. Acta Pædiatr Scand 1979a; 68: 541-545.
17. Andersen GE, Lous P, Friis-Hansen B. Hyperlipoproteinemia in newborn infants. A study of 1025 families. Acta Pædiatr Scand 1979b; 68: 683-690.
18. Andersen LK, Jensen HK, Juul S, Færgeman O. Patient attitudes to detection of heterozygous familial hypercholesterolemia. Arch Intern Med 1997; 157: 553-560.
19. Andersen LK. Familiær Hyperkolesterolæmi. Kvaliteten af Behandlingen og Psykologiske Reaktioner På Prædiktiv Testning. Aarhus University Press 1999; 1-93 (Ph.D. thesis).
20. Appleyard M, Hansen AT, Jensen G, Schnohr P, Nyboe J. The Copenhagen City Heart Study: Østerbroundersøgelsen - A book of tables with data from the first examination (1976-78) and a five year follow-up (1981-83): The Copenhagen City Heart Study Group. Scand J Soc Med Suppl. 1989; 41: 1-60.
21. Arca M, Jokinen E. Low density lipoprotein receptor mutations in a selected population of individuals with moderate hypercholesterolemia. Atherosclerosis 1998; 136: 187-194.
22. Ashkenas J, Byers PH. Gene Regulation '97. The final stage of gene expression: Chaperones and the regulation of protein fate. Am J Hum Genet 1997; 61: 267-272.
23. Assouline L, Levy E, Feoli-Fonseca JC, Godbout C, Lambert M. Familial hypercholesterolemia: Molecular, biochemical, and clinical characterization of a French-Canadian pediatric population. Pediatrics 1995; 96: 239-246.
24. Baron H, Fung S, Aydin A, Bähring S, Luft FC, Schuster H. Oligonucleotide ligation assay (OLA) for the diagnosis of familial hypercholesterolemia. Nature Biotechnology 1996; 14: 1279-1282.
25. Beaumont V, Jacotot B, Beaumont JL. Ischemic disease in men and women with familial hypercholesterolaemia and xanthomatosis. Atherosclerosis 1976; 24: 441-450.
26. Beeso J, Wong N, Ayling R, Eldridge P, Marshall W, Sherwood R, Peter T. Screening for hyperchotesterolaemia in 10,000 neonates in a multi-ethnic population. Eur J Pediatr 1999; 158: 833-837.
27. Beisiegel U, Schneider WJ, Goldstein JL, Anderson RGW, Brown MS. Monoclonal antibodies to the low density lipoprotein receptor as probes for study of receptor-mediated endocytosis and the genetics of familial hypercholesterolemia. J Biol Chem 1981; 256: 11923-11931.
28. Benhamamouch S, Kuznierz J-P, Agnani G, Marzin D, Lecerf J-M, Fruchart J-C, Clayey V. Determination of the LDL receptor binding capacity of human lymphocytes by immunocytofluorimetric assay. Biochim Biophys Acta 1988; 1002: 45-53.
29. Benlian P, de Gennes JL, Dairou F, Hermelin B, Ginon I, Villain E, Lagarde JP, Federspiel MC, Bertrand V, Bernard C, Bereziat G. Phenotypic expression in double heterozygotes for familial hypercholesterolemia and familial defective apolipoprotein B-100. Hum Mutat 1996; 7: 340-345.
30. Benuck I, Gidding SS, Donovan M, Traisman ES, Traisman HS. Usefulness of parental serum total cholesterol levels in identifying children with hypercholesterolemia. Am J Cardiol 1992; 69: 713-717.
31. Bertolini S, Lelli N, Coviello DA, Ghisellini M, Masturzo P, Tiozzo R, Elicio N, Gaddi A, Calandra S. A large deletion in the LDL receptor gene - The cause of familial hypercholesterolemia in three Italian families: A study that dates back to the 17th century (FH Pavia). Am J Hum Genet 1992; 51: 123-134.
32. Bertolini S, Cassanelli S, Garuti R, Ghisellini M, Simone ML, Rolleri M, Masturzo P, Calandra S. Analysis of LDL receptor gene mutations in Italian patients with homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1999; 19: 408-418.
33. Bilheimer DW, Goldstein JL, Grundy SM, Brown MS. Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. J Clin Invest 1975; 56: 1420-1430.
34. Bilheimer DW, Goldstein JL, Grundy SM, Starzl TE, Brown MS. Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterole in a child with homozygous familial hypercholesterolemia. N Engl J Med 1984; 1658-1664.
35. Blacklow SC, Kim PS. Protein folding and calcium binding defects arising from familial hypercholesterolemia mutations of the LDL receptor. Nature Structural Biology 1996; 3: 758-61.
36. Blades BL, Dudman NPB, Wilcken DEL. Screening for familial hypercholesterolemia in 5000 neonates: A recall study. Pediatr Res 1988; 23: 500-504.
37. Bloom D, Kaufman SR, Stevens RA. Hereditary xanthomatosis: Familial incidence of xanthoma tuberosum associated with hypercholesterolemia and cardiovascular involvement, with report of several cases of sudden death. Arch Dermatol Syphilol 1942; 45: 1-18.
38. Bochmann H, Gehrisch S, Jaross W. Fast amplification of the low density lipoprotein receptor gene and detection of a large deletion by means of long polymerase chain reaction. Eur J Clin Chem Biochem 1996; 34: 955-959.
39. Bos CR, Shank SL, Snider MD. Role of clathrin-coated vesicles in glycoprotein transport from the cell surface to the golgi complex. J Biol Chem 1995; 270: 665-671.
40. Boulton TJC, Craig IH, Hill G. Screening of cord blood low-density-lipoprotein cholesterol in the diagnosis of familial hypercholesterolaemia: A study of 2000 infants. Acta Pædiatr Scand 1979; 68: 363-370.
41. Bourbon M, Fowler AM, Sun XM, Soutar AK. Inheritance of two different alleles of the low-density lipoprotein (LDL)-receptor gene carrying the recurrent Pro664-Leu mutation in a patient with homozygous familial hypercholesterolaemia. Clin Genet 1999; 56: 225-231.
42. Brewster TG, Waite DJ, Hudson GA. Quantitation of b-lipoprotein in cord serum by rate nephelometric immunoassay: A potential screening test for familial hypercholesterolemia. Clin Chem 1982; 28: 1192-1196.
43. Briggs MR, Yokoyama C, Wang X, Brown MS, Goldstein JL. Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. 1. Identification of the protein and delineation of its target nucleotide sequence. J Biol Chem 1993; 268: 14490-14496.
44. Brorholt-Petersen JU, Jensen HK, Raungaard B, Gregersen N, Færgeman O. LDL receptor gene mutations and the hypocholesterolemic response to statin therapy. Clin Genet 2001; 59: 397-405.
45. Bross P, Corydon TJ, Andresen BS, Jorgensen MM, Bolund L, Gregersen N. Protein misfolding and degradation in genetic diseases. Hum Mutat 1999; 14: 186-198.
46. Brown MS, Goldstein JL. Expression of the familial hypercholesterolemia gene in heterozygotes: Mechanism for a dominant disorder in man. Science 1974; 185: 61-63.
47. Brown MS, Goldstein JL. Receptor-mediated control of cholesterol metabolism. Science 1976; 191: 150-154.
48. Brown MS, Kovanen PT, Goldstein JL. Regulation of plasma cholesterol by lipoprotein receptors. Science 1981; 212: 628-635.
49. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
50. Brunzell JD, Schrott HG, Motulsky AG et al. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 1976; 25: 313-320.
51. Buchwald H. Lowering of cholesterol absorption and blood levels by ileal exclusion: Experimental basis and preliminary clinical report. Circulation 1964; 29: 713-720.
52. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, et al., and the POSCH Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-955.
53. Carmena R, Lussier-Cacan S, Roy M, Minnich A, Lingenhel A, Kronenberg F, Davignon J. Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect. Arterioscler Thromb Vasc Biol 1996; 16: 129-136.
54. Carmena R, Roy M, Roederer G, Minnich A, Davignon J. Coexisting dysbetalipoproteinemia and familial hypercholesterolemia. Clinical and laboratory observations. Atherosclerosis 2000; 148: 113-124.
55. Cassanelli S, Bertolini S, Rolleri M, De Stefano F, Casarino L, Elicio N, Naselli A, Calandra S. A 'de novo' point mutation of the low-density lipoprotein receptor gene in an Italian subject with primary hypercholesterolemia. Clin Genet 1998; 53: 391-395.
56. Cavalli-Sforza LL, Piazza A. Human genomic diversity in Europe: A summary of recent research and prospects for the future. Eur J Hum Genet 1993; 1: 3-18.
57. Cavanaugh JA, Easteal S, Simons LA, Thomas DW, Serjeantson SW. FH Sidney 1 and 2: Two novel frameshift mutations in exon 10 of the lowdensity lipoprotein receptor gene detected by heteroduplex formation. Hum Mutat 1994; 4: 276-280.
58. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
59. Cenarro A, Casao E, Civeira F, Jensen HK, Faergeman O, Pocovi M. PIAI/A2 polymorphism of platelet glycoprotein IIIa and risk of acute coronary syndromes in heterozygous subjects for familial hypercholesterolemia. Atherosclerosis 1999; 143: 99-104.
60. Chan P, Edwards A, Lafrenière R, Parsons HG. Improved detection of familial hypercholesterolemia by determining low density lipoprotein receptor expression in mitogen-induced proliferating lymphocytes. J Lipid Res 1998; 39: 2261-2270.
61. Chaves FJ, Puig O, Garcia-Sogo M, Real J, Gil JV, Ascaso J, Carmena R, Armengod ME. Seven DNA polymorphisms in the LDL receptor gene: Application to the study of familial hypercholesterolemia in Spain. Clin Genet 1996; 50: 28-35.
62. Christensen NC, Hørder M. Familial hyperlipoproteinaemia. A study of 152 members of 26 families. Dan Med Bul 1971; 18: 100-104.
63. Ciccarese M, Pacifico A, Tonolo G, Pintus P, Nikoshkov A, Zuliani G, Fellin R, Luthman H, Maioli M. A new locus for autosomal recessive hypercholesterolemia maps to human chromosome 15q25-q26. Am J Hum Genet 2000; 66: 453-460.
64. Cooper DN, Krawczak M. The mutational spectrum of single base-pair substitutions causing human genetic disease: Patterns and predictions. Hum Genet 1990; 85: 55-74.
65. Cotton RGH, Rodriques NR, Duncan RD. Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations. Proc Natl Acad Sci U.S.A. 1988; 85: 4397-4401.
66. Couture P, Brun LD, Szots F, Lelièvre M, Gaudet D, Després JP, Simard J, Lupien PJ, Gagné C. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadian with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998; 18: 1007-1012.
67. Craig EA, Gambill BD, Nelson RJ. Heat shock proteins: Molecular chaperones of protein biogenesis. Microbiological Reviews 1993; 57: 402-414.
68. Cuthbert JA, East CA, Bilheimer DW, Lipsky PE. Detection of familial hypercholesterolemia by assaying functional low-density-lipoprotein receptors on lymphocytes. N Engl J Med 1986; 314: 879-883.
69. Dallongeville J, Roy M, Leboeuf N, Xhignesse M, Davignon J, Lussier-Cacan S. Apolipoprotein E polymorphism association with lipoprotein profile in endogenous hypertriglyceridemia and familial hypercholesterolemia. Arteriosclerosis and Thrombosis 1991; 11: 272-278.
70. Dammerman M, Breslow JL. Genetic basis of lipoprotein disorders. Circulation 1995; 91: 505-512.
71. Darmady JM, Fosbrooke AS, Lloyd JK. Prospective study of serum lipid cholesterol levels during first year of life. BMJ. 1972; 2: 685-688.
72. Davey-Schmidt G, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol and mortality: The Whitehall study. JAMA 1992; 267: 70-76.
73. Davis CG, Goldstein JL, Südhof TC, Anderson RGW, Russell DW, Brown MS. Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region. Nature 1987; 326: 760-765.
74. Dawson PA, van der Westhuyzen DR, Sudhof TC, Brown MS, Goldstein JL. Sterol-dependent repression of low density lipoprotein receptor promoter mediated by 16-base pair sequence adjacent to binding site for transcription factor Sp1. J Biol Chem 1988; 263: 3372-3379.
75. Day INM, Whittal R, Gudnason V, Humphries SE. Dried templates DNA, dried PCR oligonucleotides and mailing in 96-well plates: LDL receptor gene mutation screening. BioTechniques 1995; 18: 981-984.
76. Day INM, Whittall RA, O'Dell SD, Haddad L, Bolla MK, Gudnason V, Humphries SE. Spectrum of LDL receptor gene mutations in heterozygous familial hypercholesterolemia. Hum Mutat 1997a; 10: 116-127.
77. Day INM, Haddad L, O'Dell SD, Day LB, Whittall RA, Humphries SE. Idenfication of a common low density lipoprotein receptor mutation (R329X) in the south of England: Complete linkage disequilibrium with an allele of microsatellite D19S394. J Med Genet 1997b; 34: 111-116.
78. Defesche JC, van Diermen DE, Lansberg PJ, Lamping RJ, Reymer PWA, Hayden MR, Kastelein JJP. South African founder mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia in the Dutch population. Hum Genet 1993; 92: 567-570.
79. Defesche J. World Health Organisation report on familial hypercholesterolemia. Atherosclerosis 2001; 154: 242.
80. de Llano JJM, Andreu EJ, Knecht E. Use of inductively coupled plasma - Mass spectrometry for the quantitation of the binding and uptake of colloidal gold - Low-density lipoprotein conjugates by cultured cells. Analytical Biochemistry 1996; 243: 210-217.
81. de Llano JJM, Andreu EJ, Pastor A, Delaguardia M, Knecht E. Electrothermal atomic absorption spectrometric diagnosis of familial hypercholesterolemia. Anal Chem 2000; 72: 2406-2413.
82. Det Etiske Råd. Génundersøgelse af Raske - Redegørelse om Præsymptomatisk Géndiagnostik. Det Etiske Råd & Københavns Universitet 2000. (http://www.etiskraad.dk/publikationer/genl_00/index.htm).
83. Dhawan P, Chang R, Mehta KD. Identification of essential nucleotides of the FP1 element responsible for enhancement of low density lipoprotein receptor gene transcription. Nucleic Acids Res 1997; 25: 4132-4138.
84. Djordjevic JT, Bieri S, Smith R, Kroon PA. A deletion in the first cysteinerich repeat of the low-density-lipoprotein receptor leads to the formation of multiple misfolded isomers. Eur J Biochem 1996; 239: 214-219.
85. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary eevents with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
86. Dudman NPB, Blades BL, Wilcken DEL, Aitken JM. Radial immunodiffusion assay of apolipoprotein B in blood dried on filter paper - A potential screening method for familial type 11 hypercholesterolaemia. Clin Chem Acta 1985; 149: 117-127.
87. Eden ER, Naoumova RP, Burden JJ, McCarthy MI, Soutar AK. Use of homozygosity mapping to identify a region on chromosome 1 bearing a defective gene that causes autosomal recessive homozygous hypercholesterolemia in two unrelated families. Am J Hum Genet 2001; 68: 653-660.
88. Ekström U, Abrahamson M, Sveger T, Lombardi P, Nilsson-Ehle P. An efficient screening procedure detecting six novel mutations in the LDL receptor gene in Swedish children with hypercholesterolemia. Hum Genet 1995; 96: 147-150.
89. Ekström U, Abrahamson M, Wallmark A, Florén CH, Nilsson-Ehle P. Mutations in the low-density lipoprotein receptor gene in Swedish familial hypercholesterolaemia patients: Clinical expression and treatment response. Eur J Clin Invest 1998; 28: 740-747.
90. Ekstriöm U, Abrahamson M, Florén C-H, Tollig H, Wettrell G, Nilsson G, Sun X-M, Soutar AK, Nilsson Ehle P. An individual with a healthy phenotype in spite of a pathogenic LDL receptor mutation. Clin Genet 1999; 55: 332-339.
91. Ekström U, Abrahamson M, Sveger T, X-M Sun, Soutar AK, Nilsson-Ehte P. Expression of an LDL receptor allele with two different mutations (E256K and 1402T). J Clin Pathol: Mol Pathol 2000; 53: 31-36.
92. Ellison J, Dean M, Goldman D. Efficacy of fluorescence-based PCR-SSCP for detection of point mutations. BioTechniques 1993; 15: 684-691.
93. Epstein FH, Block WD, Hand EA, Francis T. Familial hypercholesterolemia, xanthomatosis and coronary heart disease. Am J Med 1959; 39-53.
94. Erkelens DW, Sherwood LM. Familial hypercholesterolemia, tendinous xanthomas, and Frans Hals. JAMA 1989; 262: 2092.
95. Esser V, Russel DW. Transport-deficient mutations in the low density lipoprotein receptor: Alterations in the cysteine-rich and cysteine-poor regions of the protein block intracellular transport. J Biol Chem 1988; 263: 13276-13281.
96. Eto M, Watanabe K, Chonan N, Ishii K. Familial hypercholesterolemia and apolipoprotein E4. Atherosclerosis 1988; 72: 123-128.
97. Fagge CH. X. Diseases, etc., of the skin 1; General xanthelasma or vitiligoidea. Trans Pathol Soc 1873; 24: 242-250.
98. Fass D, Blacklow S, Kim PS, Berger JM. Molecular basis of familial hypercholesterolaemia from structure of LDL receptor module. Nature 1997; 388: 691-693.
99. Ferrières J, Sing CF, Roy M, Davignon J, Lussier-Cacan S. Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia. Sex-specific effects. Arterioscler Thromb 1994; 14: 1553-1560.
100. Ferrières J, Lambert J, Lussier-Cacan S, Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 1995; 92: 290-295.
101. Feussner G, Dobmeyer J, Nissen H, Hansen TS. Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type 1II hyperlipoproteinemia. Am J Med Genet 1996; 65: 149-154.
102. Figueiredo MS, Dos Santos JE, Fernando LA, Zago MA. High frequency of the Lebanese allele of the LDLr gene among Brazilian patients with familial hypercholesterolaemia. J Med Genet 1992; 29: 813-815.
103. Fourie AM, Coetzee GA, Gevers W, van der Westhuyzen DR. Two mutant low-density-lipoprotein receptors in Afrikaners slowly processed to surface forms exhibiting rapid degradation or functional heterogeneity. Biochem J 1988; 255: 411-415.
104. Fourie AM, Coetzee GA, Gevers W, van der Westhuyzen DR. Low-density lipoprotein receptor point mutation results in expression of both active and inactive surface forms of the same mutant receptor. Biochemistry 1992; 31: 12754-12759.
105. Fox TC. A case of xanthelasma multiplex. Lancet 1879; 2: 688-689.
106. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - An integrated approach to mechanisms and disorders. N Engl J Med 1967; 276: 34-44, 94-103, 148-156, 215-226, 273-281.
107. Friedlander Y, Leitersdorf E. Influence of apolipoprotein E genotypes on plasma lipid and lipoprotein concentrations: Results from a segregation analysis in pedigrees with molecularly defined familial hypercholesterolemia. Genetic Epidemiology 1996; 13: 159-177.
108. Friedewald WT, Levy FI, Fredrickson DS: Estimation of the concentration of the low density lipoprotein cholesterol in plasma without use af the preparative ultracentrifuge. Clin Chem 1972; 18: 499-509.
109. Frikke-Schmidt R, Arlien-Søborg P, Thorsen S, Jensen HK, Vorstrup S. LDL receptor mutations and apoB mutations are not risk factors for ischemic cerebrovascular disease of the young, but lipids and lipoproteins are. Eur J Neurol 1999; 6: 691-696.
110. Fumeron F, Grandchamp B, Fricker J, Krempf M, Wolf LM, Khayat MC, Boiffard O, Apfelbaum M. Presence of the French Canadian deletion in a French patient with familial hypercholesterolemia. N Engl J Med 1992; 326: 69.
111. Færgeman O, Meinertz H, Hylander E, Fisherman K, Jarnum S, Nielsen OV. Effects and side effects of partial ileal bypass surgery for familial hypercholesterolemia. Gut 1982; 23: 558-563.
112. Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, Calandra S, Bertolini S, Cossu F, Grishin N, Barnes R, Cohen JC, Hobbs HH. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001; 292: 1394-1398.
113. Gaudet D, Vohl MC, Perron P, Tremblay G, Gagné C, Lesiège D, Bergeron J, Moorjani S, Després JP. Relationships of abdominal obesity and hyperinsulinemia to angiographically assesed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation 1998; 97: 871-877.
114. Gaudet D, Vohl MC, Couture P, Moorjani S, Tremblay G, Perron P, Gagné C, Després JP. Contribution of receptor negative versus receptor defective mutations in the LDL-receptor gene to angiographically assessed coronary artery disease among young (25-49 years) versus middle-aged (50-64 years) men. Atherosclerosis 1999; 143: 153-161.
115. Geisel J, Gielen J, Oette K, Herrmann W, Wielckens K. Mutation analysis of exon 3 of the LDL receptor gene in patients with severe hypercholesterolemia. Clin Chem Lab Med 1998; 36: 279-282.
116. Geisel J, Walz T, Bodis M, Nauck M, Oette K, Herrmann W. Fluorescence-based single-strand conformation polymorphism analysis of the low density lipoprotein receptor gene by capillary electrophoresis. Journal of Chromatography B 1999; 724: 239-247.
117. Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PWF, Salem DN, Schaefer EJ. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85: 2025-2033.
118. Gidding SS, Bookstein LC, Chomka EV. Usefulness of electron beam tomography in adolescents and young adults with heterozygous familial hypercholesterolemia. Circulation 1998; 98: 2580-2583.
119. Glueck CJ, Heckman F, Schoenfeld M, Steiner P, Pearce W. Neonatal familial type II hyperlipoproteinemia: Cord blood cholesterol in 1800 births. Metabolism 1971; 20: 597-608.
120. Goldman L, Goldman PA, Williams LW, Weinstein ML. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am J Cardiol 1993; 72: 75D-79D.
121. Goldstein JL, Hazzard WR, Schrott HG, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest 1973a; 52: 1533-1543.
122. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973b; 52: 1544-1568.
123. Goldstein JL, Brown MS. Binding and degradation of low density lipoproteins by cultured human fibroblasts. J Biol Chem 1974; 249: 5153-5162.
124. Goldstein JL, Albers JJ, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Plasma lipid levels and coronary heart disease in adult relatives of newborns with normal and elevated cord blood lipids. Am J Hum Genet 1974; 26: 727-735.
125. Goldstein JL, Sobhani MK, Faust JR, Brown MS. Heterozygous familial hypercholesterolemia: Failure of normal allele to compensate for mutant allele at a regulated gene locus. Cell 1976; 9: 195-203.
126. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia, in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Disease, Ed. 7. McGraw-Hill Book Co, New York, 1995, pp 1981-2030.
127. Gofman JW, Delalla O, Glazier F, Freeman NK, Lindgren FT, Nichols AV, Strisower B, Tamplin AR. The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis and coronary heart disease. Plasma 1954a; 2: 413-484.
128. Gofman JW, Rubin L, McGinley JP, Jones HB. Hyperlipoproteinemia. Am J Med 1954b; 17: 514-520.
129. Graadt van Roggen JF, van der Westhuyzen DR, Coetzee GA, Marais AD, Steyn K, Langenhoven E, Kotze MJ. FH Afrikaner-3 LDL receptor mutation results in defective LDL receptors and causes a mild form of familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15: 765-772.
130. Graham CA, McClean E, Ward AJM, Beattie ED, Martin S, O'Kane M, Young IS, Nicholls DP. Mutation screening and genotype: Phenotype correlation in familial hypercholesterolaemia. Atherosclerosis 1999; 147: 309-316.
131. Grossman M, Raper SE, Kozarsky K, Stein EA, Engelhardt JF, Muller D, Lupien PJ, Wilson JM. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nature Genetics 1994; 6: 335-341.
132. Grossman M, Rader DJ, Muller DWM, Kolansky DM, Kozarsky K, Clark III BJ, Lupien PJ, Brewer HB, Raper SE, Wilson JM. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nature Medicine 1995; 1: 1148-1154.
133. Gudnason V, Day INM, Humphries SE. Effect on plasma lipid levels of different classes of mutations in the low-density lipoprotein receptor gene in patients with familial hypercholesterolemia. Arterioscler Thromb 1994; 14: 1717-1722.
134. Gudnason V, Patel D, Sun XM, Humphries S, Soutar AK, Knight BL. Effect of the Stul polymorphism in the LDL receptor gene (Ala 370 to Thr) on lipid levels in healthy individuals. Clin Genet 1995; 47: 68-74.
135. Gudnason V, Sigurdsson G, Nissen H, Humphries SE. Common founder mutation in the LDL receptor gene causing familial hypercholesterolaemia in the Icelandic population. Hum Mutat 1997; 10: 36-44.
136. Guravich JL. Familial hypercholesteremic xanthomatosis. A preliminary report. I. Clinical, electrocardiographic and laboratory considerations. Am J Med 1959; 24: 8-29.
137. Gylling H, Aalto-Setälä, Kontula K, Miettinen TA. Serum low density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymophism and by the FH-Helsinki mutation of the low density lipoprotein receptor gene in familial hypercholesterolemia. Arteriosclerosis and Thrombosis 1991; 11: 1368-1375.
138. Haddad L, Day LB, Attwood J, Povey S, Humphries SE, Day INM. Development of a microsatellite-based approach to co-segregation analysis of familial hypercholesterolaemic kindreds. Ann Hum Genet 1997; 61: 497-506.
139. Haddad L, Day INM, Hunt S, Williams RR, Humphries SE, Hopkins PN. Evidence for a third genetic locus causing familial hypercholesterolemia: A non-LDLR, non-APOB kindred. J Lipid Res 1999; 40: 1113-1122.
140. Hansen PS, Rüdiger N, Tybjærg-Hansen A, Færgeman O, Gregersen N: Detection of the apoB-3500 mutation by gene amplification and cleavage with Msp1. J Lipid Res 1991; 32: 1229-1233.
141. Hansen PS, Jensen HK, Meinertz H, Hansen AB, Klausen IC, Gerdes LU, Hørder M, Gregersen N, Færgeman O. Association between apolipoprotein B and apolipoprotein E polymorphism and lipid variation, effect of lipid lowering therapy, and atherosclerotic disease in heterozygous familial hypercholesterolemia. Nutr Metab Cardiovasc Dis 1994a; 4: 204-208.
142. Hansen PS, Meinertz H, Jensen HK, Fruergaard P, Launbjerg J, Klausen IC Lemming L, Gregersen N, Faergeman O. Biochemical, genetic and clinical characteristics of 46 heterozygous mutation carriers and 57 normal relatives from 5 Danish families with familial defective apolipoprotein B-100. Arteriosclerosis and Thrombosis 1994b; 14: 207-213.
143. Hansen PS. Familial defective apolipoprotein B-100. Dan Med Bull 1998; 45: 370-382.
144. Harbitz F. Tumors of tendon sheaths, joint capsules and multiple xanthomas. Arch Pathol 1927; 4: 507-527.
145. Hausmann D, Johnson JA, Sudhir K, Mullen WL, Friedrich G, Fitzgerald PJ, Chou TM, Ports TA, Kane JP, Malloy MJ, Yock PG. Angiographically silent atherosclerosis detected by intravascular ultrasound in patients with familial hypercholesterolemia and familial combined hyperlipidemia: Correlation with high density lipoproteins. J Am Coll Cardiol 1996; 27: 1562-1570.
146. Hayashi K. PCR-SSCP: A simple and sensitive method for detection of mutations in the genomic DNA. PCR Methods Applic 1991; 1: 34-38.
147. Hayashi K, Yandell DW. How sensitive is PCR-SSCP? Human Mutation 1993; 2: 338-346.
148. Heath KE, Gudnason V, Humphries SE, Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1999; 143: 41-54.
149. Heath KE, Day INM, Humphries SE. Universal primer quantitative fluorescent multiplex (UPQFM) PCR: A method to detect major and minor rearrangements of the low density lipoprotein receptor gene. J Med Genet 2000a; 37: 272-280.
150. Heath KE, Whitall RA, Miller GJ, Humphries S. 1705 Variant in the low density lipoprotein receptor gene has no effect on plasma cholesterol levels. J Med Genet 2000b; 37: 713-715.
151. Heath KE, Gahan M, Whittall RA, Humphries SE. Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolemia:
152. Hegele PA, Emi M, Wu LL, Hopkins PN, Williams RR, Lalouel JM. Clinical application of deoxyribonucleic acid markers in a Utah family with hypercholesterolemia. Am J Cardiol 1989; 63: 109-112.
153. Heiberg A, Berg K. The inheritance of hyperlipoproteinaemia with xanthomatosis. A study of 132 kindreds. Clin Genet 1976; 9: 203-233.
154. Heiberg A, Slack J. Family similarities in the age at coronary death in familial hypercholesterolaemia. BMJ 1977; 2: 293-295.
155. Hirschhorn K, Wilkinson CF. The mode of inheritance in essential familial hypercholesterolemia. Am J Med 1959; 26: 60-67.
156. Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arteriosclerosis and Thrombosis 1991; 11: 290-297.
157. Ho YK, Brown MS, Bilheimer DW, Goldstein JL. Regulation of low density lipoprotein receptor activity in freshly isolated human lymphocytes. J Clin Invest 1986; 58: 1465-1474.
158. Hobbs HH, Leitersdorf E, Leffert CC, Cryer DR, Brown MS, Goldstein JL. Evidence for a dominant gene that suppresses hypercholesterolemia in a family with defective lipoprotein receptors. J Clin Invest 1989; 84: 656-664.
159. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: Mutational analysis of a membrane protein. Annu Rev Genet 1990; 24: 133-170.
160. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1: 445-466.
161. Hoeg JM, Feuerstein IM, Tucker EE. Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb 1994; 14: 1066-1074.
162. Hopkins P, Wu LL, Schumacher MC, Emi M, Hegele RM, Hunt SC, Lalouel JM, Williams RR. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction. Arteriosclerosis and Thrombosis 1991; 11: 1137-1146.
163. Hopkins PN, Stephenson S, Wu LL, Riley WA, Xin Y, Hunt SC. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2001; 87: 547-553.
164. Humphries S, Taylor R, Jeenah M, Dunning A, Horsthemke B, Seed M, Schuster H, Wolfram G. Gene probes in diagnosis of familial hypercholesterolemia. Arteriosclerosis 1989; Supplement 19: I-59-I-65.
165. Humphries S, King-Underwood L, Gudnason V, Seed M, Delattre S, Clavey V, Fruchart JC. Six DNA polymorphisms in the low density lipoprotein receptor gene: Their genetic relationship and an example of their use for identifying affected relatives of patients with familial hypercholesterolaemia. J Med Genet 1993; 30: 273-279.
166. Humphries SE, Gudnason V, Whittall R, Day INM. Single-strand conformation polymorphism analysis with high throughput modifications, and its use in mutation detection in familial hypercholesterolemia. Clin Chem 1997; 43: 427-435.
167. Hunt SC, Hopkins PN, Bulka K, Mcdermott MT, Thorne TL, Wardell BB, Bowen BR, Ballinger DG, Skolnick MH, Samuels ME. Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 1089-1093.
168. Illingworth RD. How effective is drug therapy in heterozygous familial hypercholesterolemia? Am J Cardiol 1993; 72: 54D-58D.
169. Ilmonen M, Ebeling T, Viikari J, Ojala JP, Tikkanen MJ. Screening of the 3′ two-thirds of the coding area of the apo B gene in Finnish hypercholesterolemic patients. Report of six new genetic variants. Atherosclerosis 1997; 128: 191-199.
170. Innerarity TL, Weisgraber KH, Arnold KS, Mahley RW, Krauss RM, Vega GL, Grundy SM. Familial defective apolipoprotein B-100: Low-density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA 1987; 84: 6919-6923.
171. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, McCarthy BJ: Familial defective apolipoprotein B-100: A mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 1990; 31: 1337-1350.
172. Iwahana H, Fujimura M, Takahashi Y, Iwabuchi T, Yoshimoto K, Itakura M. Multiple fluorescence-based PCR-SSCP analysis using internal fluorescent labeling of PCR products. Biotechniques 1996; 21: 510-519.
173. Jeenah M, September W, van Roggen FG, de Villiers W, Seftel H, Marais D. Influence of specific mutations at the LDL-receptor locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1993; 98: 51-58.
174. Jensen HK, Jensen TG, Jensen LG, Hansen PS, Kjeldsen M, Andresen BS, Nielsen V, Meinertz H, Hansen AB, Bolund L, Faergeman O, Gregersen N. Characterization of a disease-causing Glu119-Lys mutation in the low density lipoprotein receptor gene in two Danish families with heterozygous familial hypercholesterolemia. Hum Mutat 1994a; 4: 102-113.
175. Jensen HK, Jensen LG, Hansen PS, Petersen LS, Gerdes LU, Bolund L, Færgeman O, Gregersen N. An Alanine29-Serine variant in exon 2 of the low density lipoprotein receptor gene: No association with hypercholesterolemia. Clin Genet 1994b; 46: 214-215.
176. Jensen HK. Methods of Mutation Detection with Special Reference to the Low Density Lipoprotein Receptor Gene in Familial Hypercholesterolemia. Aarhus University Press 1995; 1-54 (Ph.D. thesis).
177. Jensen HK, Jensen LG, Hansen PS, Faergeman O, Gregersen N. An IranianArmenian frameshift mutation causing familial hypercholesterolemia. Clin Genet 1996; 49: 88-90.
178. Jensen J, Blankenhorn DH, Kornerup V. Coronary Disease in Familial Hypercholesterolemia. Circulation 1967; 36: 77-82.
179. Jensen JM, Gerdes LU, Jensen HK, Christiansen TM, Brorholt-Petersen JU, Færgeman O. Prediction of coronary heart disease by rate of aorto-coronary calcification in patients with familial hypercholesterolemia. J Intern Med 2000; 247: 479-484.
180. Jensen LG, Jensen HK, Heath F, Kjeldsen M, Færgeman O, Kølvraa S, Bolund L, Gregersen N. Allele-specific measurement of low-density lipoprotein receptor transcript levels. Hum Mutat 1996a; 8: 126-133.
181. Jensen LG, Jensen HK, Nissen H, Kristiansen K, Færgeman O, Bolund L, Gregersen N. An LDL receptor promoter mutation in a heterozygous FH patient with dramatically skewed ratio between the two allelic mRNA variants. Hum Mutat 1996b; 7: 82-84.
182. Jensen TG, Andresen BS, Jensen HK, Jensen LG, Heath F, Pedersen S, Nielsen V, Jensen UB, Lund TB, Gregersen N, Kølvraa S, Bolund L. Rapid characterization of disease-causing mutations in the low density lipoprotein receptor (LDL-R) gene by overexpression in COS cells. German Journal of Gastroenterology (Suppl. 3) 1996; 34: 9-11.
183. Jørgensen MM, Jensen ON, Holst HU, Hansen JJ, Corydon TJ, Bross P, Bolund L, Gregersen N. Grp78 is involved in retention of mutant low density lipoprotein receptor protein in the endoplasmic reticulum. J Biol Chem 2000; 275: 33861-33868.
184. Kajinami K, Yagi K, Higashikata T, Inazu A, Koizumi J, Mabuchi H. Lowdensity lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia. Am J Cardiol 1998; 82: 113-117.
185. Kajinami K, Mabuchi H. Therapeutic effects of LDL apheresis in the prevention of atherosclerosis. Curr Opin Lipidol 1999; 10: 383-386.
186. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264: 3007-3012.
187. Kane JP, Malloy MJ, Tun P, Phillips NR, Freedman DD, Williams ML, Rowe JS, Havel RJ. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med 1981; 304: 251-258.
188. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study. Ann Intern Med 1971; 74: 1-12.
189. Kawasuji M, Sakakibara N, Fujii S, Yasuda T, Watanabe Y. Coronary artery bypass surgery with arterial grafts in familial hypercholesterolemia. J Thorac Cardiovasc Surg 2000; 119: 1008-1013.
190. Khachadurian AK. The inheritance of essential familial hypercholesterolemia. Am J Med 1964; 37: 402-407.
191. Khachadurian AK, Uthman SM. Experiences with the homozygous cases of familial hypercholesterolemia. Nutr Metabol 1973; 15: 132-140.
192. Kim SH, Bae JH, Chae JJ, Kim UK, Choe SJ, Namkoong Y, Kim HS, Park YB, Lee CC. Long-distance PCR-based screening for large rearrangements of the LDL receptor gene in Korean patients with familial hypercholesterolemia. Clin Chem 1999; 45: 1424-1430.
193. Knipscheer HC, Boelen CCA, Kastelein JJP, van Diermen DE, Groenemeijer BE, van den Ende A, Büller HR, Bakker HD. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 1996; 39: 867-871.
194. Knoblauch H, Müller-Myhsok B, Busjahn A, Ben Avi L, Bahring S, Baron H, Heath SC, Uhlmann R, Faulhaber HD, Shpitzen S, Aydin A, Reshef A, Rosenthal M, Eliav O, Muhl A, Lowe A, Schurr D, Harats D, Jeschke E, Friedlander Y, Schuster H, Luft FC, Leitersdorf E. A cholesterol-lowering gene maps to chromosome 13q. Am J Hum Genet 2000; 66: 157-166.
195. Koivisto PVI, Koivisto UM, Miettinen TA, Kontula K. Diagnosis of heterozygous familial hypercholesterolemia. DNA Analysis complements clinical examination and analysis of serum lipid levels. Arteriosclerosis and Thrombosis 1992; 12: 584-592.
196. Koivisto PVI, Koivisto UM, Kovanen PT, Gylling H, Miettinen TA, Kontula K. Deletion of exon 15 of the LDL receptor gene is associated with a mild form of familial hypercholesterolemia FH-Espoo. Arteriosclerosis and Thrombosis 1993; 13: 1680-1688.
197. Koivisto UM, Hamalainen L, Taskinen MR, Kettunen K, Kontula K. Prevalence of familial hypercholesterolemia among young north Karelian patients with coronary heart disease: A study based on diagnosis by polymerase chain reaction. J Lipid Res 1993; 34: 269-277.
198. Koivisto UM, Palvimo JJ, Jänne OA, Kontula K. A single-base substitution in the proximal Sp1 site of the human low density lipoprotein receptor promoter as a cause of heterozygous familial hypercholesterolemia. Proc Natl Acad Sci 1994; 91: 10526-10530.
199. Koivisto UM, Viikari JS, Kontula K. Molecular characterization of minor gene rearrangements in Finnish patients with heterozygous familial hypercholesterolemia: Identification of two common missense mutations (Gly823→Asp and Leu380→His) and eight rare mutations of the LDL receptor gene. Am J Hum Genet 1995; 57: 789-797.
200. Koivisto UM, Gylling H, Miettinen TA, Kontula K. Familial moderate hypercholesterolemia caused by Asp235→Glu mutation of the LDL receptor gene and co-occurrence of a de novo deletion of the LDL receptor gene in the same family. Arterioscler Thromb Vasc Biol 1997; 17: 1392-1399.
201. Kornerup V. Familiær Hypercholesterolæmi og Xanthomatose. 1948, Konrad Jørgensens Bogtrykkeri, Kolding, Denmark (Doctoral thesis).
202. Kotze MJ, Langenhoven E, Retief AE, Seftel HC, Henderson HE, Weich HFH. Haplotypes identified by 10 DNA restriction fragment length polymorphisms at the human low density lipoprotein receptor gene locus. J Med Genet 1989; 26: 255-259.
203. Kotze MJ, Langenhoven E, Warnich L, Du Plesis L, Retief AE. The molecular basis and diagnosis of familial hypercholesterolemia in South African Afrikaners. Ann Hum Genet 1991; 55: 115-121.
204. Kotze MJ, Langenhoven E, Kriek JA, Oosthuizen CJJ, Retief AE. DNA screening of hyperlipidemic Afrikaners for familial hypercholesterolemia. Clin Genet 1992; 42: 43-46.
205. Kotze MJ, De Villers WJS, Steyn K, Kriek JA, Marais AD, Langenhoven E, Herbert JS, Graadt Van Roggen JF, Van der Westhuyzen DR, Coetzee GA. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb 1993a; 13: 1460-1468.
206. Kotze MJ, Davis HJ, Bissbort S, Langenhoven E, Brusnicky J, Oosthuizen CJJ. Intrafamilial variability in the clinical expression of familial hypercholesterolemia: Importance of risk factor determination for genetic counselling. Clin Genet 1993b; 43: 295-299.
207. Kotze MJ, Theart L, Peeters A, Langenhoven E. A de novo duplication in the low density lipoprotein receptor gene. Hum Mutat 1995; 6: 181-183.
208. Kotze MJ, de Villiers JNP, Loubser O, Thiart R, Scholtz CL, Raal FJ. A double mutant LDL receptor allele in a Cypriot family with heterozygous familial hypercholesterolemia. Hum Genet 1997; 100: 101-103.
209. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single basepair substitutions in mRNA splice junctions of human genes: Causes and consequences. Hum Genet 1992; 90: 41-54.
210. Kwiterowich Jr PO, Levy RI, Fredrickson DS. Neonatal diagnosis of familial type-II hyperlipoproteinaemia. Lancet 1973; 1: 118-122.
211. Kwiterovich PO, Fredrickson DS, Levy RI. Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic, and clinical presentation in childhood. J Clin Invest 1974; 53: 1237-1249.
212. Lambert M, Lupien PJ, Gagné, Lévy E, Blaichman S, Langlois S, Hayden M, Rose V, Clarke JTR, Wolfe BMJ, Clarson C, Parsons H, Stephure DK, Potvin D, Lambert J, the Canadian Lovastatin in children study group. Treatment of familial hypercholesterolemia in children and adolescents: Effects of lovastatin. Pediatrics 1996; 97: 619-828.
213. Landsberger D, Meiner V, Reshef A, Levy Y, van der Westhuyzen DR, Coetzee GA, Leitersdorf E. A nonsense mutation in the LDL receptor gene leads to familial hypercholesterolemia in the Druze sect. Am J Hum Genet 1992; 50: 427-433.
214. Law S, Lackner KJ, Hospattankar AV, Anchors JM, Sakaguchi AY, Naylor SL, Brewer HB. Human apolipoprotein B-100: Cloning, analysis of liver mRNA, and assignment of the gene to chromosome 2. Proc Natl Acad Sci USA 1985; 82: 8340-8344.
215. Lee WK, Haddad L, Macleod MJ, Dorrance AM, Wilson DJ, Gaffney D, Dominiczak, Packard CJD, Day INM, Humphries SE, Dominiczak AF. Identification of a common low density lipoprotein receptor mutation (C163Y) in the west of Scotland. J Med Genet 1998; 35: 573-578.
216. Lees RS, Cashin-Hemphill L, Lees AM. Non-pharmacological lowering of low-density lipoprotein by apheresis and surgical techniques. Curr Opin Lipidol 1999; 10: 575-579.
217. Lehrman MA, Schneider WJ, Brown MS, Davis CG, Elhammer A, Russell DW, Goldstein JL. The Lebanese allele at the low density lipoprotein receptor locus. J Biol Chem 1987; 262: 401-410.
218. Lehzen G, Knauss K. Uber xanthoma multiplex planum, tuberosum, mollusciforme. Arch Pathol Anat Physiol 1889; 116: 85-104.
219. Leitersdorf E, Chakravarti A, Hobbs HH. Polymorphic DNA haplotypes at the LDL receptor locus. Am J Hum Genet 1989; 44: 409-421.
220. Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, Dann EJ, Landsberger D, Sehayek E, Meiner V, Wurm M, Bard JM, Fruchart JC, Stein Y. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor Fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation 1993a; 87 (suppl III): III-35-III-44.
221. Leitersdorf E, Reshef A, Meiner V, Dann EJ, Beigel Y, Graadt van Roggen F, van der Westhuyzen DR, Coetzee GA. A missense mutation in the low density lipoprotein receptor gene causes familial hypercholesterolemia in Sephardic Jews. Hum Genet 1993b; 91: 141-147.
222. Leitersdorf E, Murratti EN, Eliav O, Peters TK. Efficacy and safety of triple therapy (Fluvastatin-Bezafibrate-Cholestyramine) for severe familial hypercholesterolemia. Am J Cardiol 1995; 76: 84A-88A.
223. Leren TP, Solberg K, Rødningen OK, Ose L, Tonstad S, Berg K. Evaluation of runing conditions for SSCP analysis: Application of SSCP for detection of point mutations in the LDL receptor gene. PCR Methods Appl 1993; 3: 159-62.
224. Leren TP, Solberg K, Rødningen OK, Tonstad S, Ose L. Two founder mutations in the LDL receptor gene in Norwegian familial hypercholesterolemia subjects. Atherosclerosis 1994; 111: 175-82.
225. Leren TP, Sundvold H, Rødningen OK, Tonstad S, Solberg K, Ose L, Berg K. Screening for known mutations in the LDL receptor gene causing familial hypercholesterolemia. Hum Genet 1995; 95: 671-676.
226. Leren TP, Hjermann I. Is responsiveness to lovastatin in familial hypercholesterolaemia heterozygotes influenced by the specific mutation in the low-density lipoprotein receptor gene? Eur J Clin Invest 1995; 25: 967-973.
227. Leren TP, Tonstad S, Gundersen KE, Bakken KS, Rødningen OK, Sundvold H, Ose L, Berg K. Molecular genetics of familial hypercholesterolemia in Norway. J Intern Med 1997; 241: 185-194.
228. Lestavel-Delattre S, Benhamamouch S, Agnani G, Luc G, Bard JM, Brousseau T, Billardon C, Kusnierz JP, de Gennes JL, Fruchart JC, Clavey V. Evidence of non-deficient low-density lipoprotein receptor patients in a pool of subjects with clinical familial hypercholesterolemia profile. Metabolism 1994; 43: 397-402.
229. Lind S, Eriksson M, Rystedt E, Wiklund O, Angelin B, Eggertsen G. Low frequency of the common Norwegian and Finnish LDL-receptor mutations in Swedish patients with familial hypercholesterolemia. J Intern Med 1998; 244: 19-25.
230. Lindgren V, Luskey KL, Russel DW, Francke U. Human genes involved in cholesterol metabolism: Chromosomal mapping of the loci for the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzymeA reductase with cDNA probes. Proc Natl Acad Sci USA 1985; 82: 8567-71.
231. Lingenhel A, Kraft HG, Kotze M, Peeters A, Kronenberg F, Kruse R, Utermann G. Concentrations of the atherogenic Lp(a) are elevated in FH. Eur J Hum Genet 1998; 6: 50-60.
232. Liu J, Ahlborn TE, Briggs MR, Kraemer FB. Identification of a novel sterol-independent regulatory element in the human low density lipoprotein receptor promoter. J Biol Chem 2000; 275: 5214-5221.
233. Lombardi P, de Wit E, Frants RR, Havekes LM. Characterisation of the LDL receptor in Epstein-Barr virus transformed lymphocytes. Biochim Biophys Acta 1990; 1044: 127-132.
234. Lombardi P, Sijbrands EJG, van de Giessen K, Smelt AHM, Kastelein JJP, Frants RR, Havekes LM. Mutations in the low density lipoprotein receptor gene of familial hypercholesterolemic patients detected by denaturing gradient gel electrophoresis and direct sequencing. J Lipid Res 1995; 36: 860-867.
235. Lombardi P, Kamerling SWA, Defesche JC, Kastelein JJP, Havekes LM. Identification of a double mutation in the low-density lipoprotein receptor gene causing familial hypercholesterolemia. Clin Genet 1996; 50: 525-526.
236. Lombardi P, Sijbrands EJG, Kamerling S, Leuven JAG, Havekes LM. The T7051 mutation of the low density lipoprotein receptor gene (FH Paris-9) does not cause familial hypercholesterolemia. Hum Genet 1997; 99: 106-107.
237. Lombardi MP, Redeker EJW, Defesche JC, Kamerling SWA, Mannens MMAM, Havekes LM, Kastelein JJP. Molecular testing for familial hypercholesterolemia: Spectrum of LDL receptor gene mutations in the Netherlands. Clin Genet 2000; 57: 116-124.
238. Ludwig EH, Hopkins PN, Allen A, Wu LL, Williams RR, Anderson JL, Ward RH, Lalouel JM, Innerarity TL. Association of genetic variations in apolipoprotein B with hypercholesterolemia, coronary artery disease, and receptor binding of low density lipoproteins. J Lipid Res 1997; 38: 1361-1373.
239. Mabuchi H, Haba T, Ueda K, Ueda R, Tatami R, Ito S, Kametani T, Koizumi J, Miyamoto S, Ohta M, Takeda R, Takegoshi, Takeshita H. Serum lipids and coronary heart disease in heterozygous familial hypercholesterolemia in the hokuriku district of Japan. Atherosclerosis 1977; 28: 417-423.
240. Mabuchi H, Tatami R, Haba T, Ueda K, Ueda R, Kametani T, Itoh Seigo, Koizumi J, Oota M, Miyamoto S, Takeda R. Homozygous familial hypercholesterolemia in Japan. Am J Med 1978; 65: 290-97.
241. Mabuchi H, Miyamoto S, Ueda K, Oota M, Takegoshi T, Wakasugi T, Takeda R. Causes of death in patients with familial hypercholesterolemia. Atherosclerosis 1986; 61: 1-6.
242. Mabuchi H, Koizumi J, Shimizu M, Takeda R, the Hokuriku FH-CHD study group. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989; 79: 225-232.
243. Mak YT, Pang CP, Tomlinson B, Zhang J, Chan YS, Mak TWL, Masarei JRL. Mutations in the low-density lipoprotein receptor gene in Chinese familial hypercholesterolemia patients. Arterioscler Thromb Vasc Biol 1998; 18: 1600-1605.
244. Makino R, Yasyu H, Kishimoto Y, Sekiya T, Hayashi K. F-SSCP: Fluorescence-based polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis. PCR Methods Appl 1992; 2 (1): 10-13.
245. Malloy MJ, Kane JP, Kunitake ST, Tun P. Complementarity of Colestipol, Niacin, and Lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med 1987; 107: 616-623.
246. Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J. Atorvastatin: An effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 1527-1531.
247. Maruyama T, Miyake Y, Tajima S, Harada-Shiba M, Yamamura T, Tsushima M, Kishino B, Horiguchi Y, Funahashi T, Matsuzawa Y, Yamamoto A. Common mutations in the low-density-lipoprotein-receptor gene causing familial hypercholesterolemia in the Japanese population. Arterioscler Thromb Vasc Biol 1995; 15: 1713-1718.
248. Mehta KD, Chang R, Norman J. Chiloscyllium plagiosum low-density lipoprotein receptor: Evolutionary conservation of five different functional domains. J Mol Evol 1996; 42: 264-272.
249. Meiner V, Landsberger D, Berkman N, Reshef A, Segal P, Seftel HC, van der Westhuyzen DR, Jeenah MS, Coetzee GA, Leitersdorf E. A common Lithuanian mutation causing familial hypercholesterolemia in Ashkenazi Jews. Am J Hum Genet 1991; 49: 443-449.
250. Miettinen TA, Gylling H. Mortality and cholesterol metabolism in familial hypercholesterolemia. Long-term follow-up of 96 patients. Arteriosclerosis 1988; 8: 163-167.
251. Minnich A, Roy M, Chamberland A, Lavigne J, Davignon J. New methods for rapid detection of low-density lipoprotein receptor and apolipoprotein B gene mutations causing familial hypercholesterolemia. Clin Biochem 1995; 28: 277-284.
252. Miserez AR, Keller U. Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15: 1719-1729.
253. Moorjani S, Gagné C, Lupien PJ, Brun D. Plasma triglycerides related decrease in high-density lipoprotein cholesterol and its association with myocardial infarction in heterozygous familial hypercholesterolemia. Metabolism 1986; 35: 311-316.
254. Moorjani S, Roy M, Gagne C, Davignon J, Brun D, Toussaint M, Lambert M, Campeau L, Blaichman S, Lupien P. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis 1989; 9: 211-216.
255. Moorjani S, Roy M, Torres A, Bétard C, Gagné C, Lambert M, Brun D, Davignon J, Lupien P. Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolemia. Lancet 1993; 341: 1303-06.
256. Moreiras O, van Staveren WA, Amorim Cruz JA, Nes M, Lund-Larsen K. Intake of energy and nutrients. Eur J Clin Nutr 1991; 45 (Suppl. 3): 105-119.
257. Müller C. Xanthomata, hypercholesterolemia, angina pectoris. Acta Med Scand 1938; 89 (suppl): 75-84.
258. Müller C. Angina pectoris in hereditary xanthomatosis. Arch Intern Med 1939; 64: 675-700.
259. Myant NB. Familial defective apolipoprotein B-100: A review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis 1993; 104: 1-18.
260. Myers RM, Larin Z, Maniatis T. Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA: DNA duplexes. Science 1985a; 230: 1242-1246.
261. Myers RM, Fishers SG, Lerman LS, Maniatis T. Nearly all single base substitutions in DNA fragments joined to a GC-clamp can be detected by denaturing gradient gel electrophoresis. Nucleic Acids Res 1985b; 13: 3131-3145.
262. Neaton JD, Blackburn H, Jakobs D. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992; 152: 1490-1500.
263. Nikkila EA, Aro A. Family study of serum lipids and lipoproteins in coronary heart disease. Lancet 1973; 1: 954-958.
264. Nissen H, Hansen AB, Guldberg P, Petersen NE, Larsen ML, Haghfelt T, Kristiansen K, Hørder M. Detection of a single base deletion in codon 424 of the low density lipoprotein receptor gene in a Danish family with familial hypercholesterolemia. Atherosclerosis 1994; 111: 209-215.
265. Nissen H, Hansen AB, Jensen HK. Detection of a frequent Hhal polymorphism in intron 9 of the low density lipoprotein receptor gene by denaturing gradient gel electrophoresis. Clin Genet 1995a; 48: 221-222.
266. Nissen H, Hansen AB, Guldberg P, Petersen NE, Larsen ML, Haghfelt T, Kristiansen K, Hørder M. Genetic diagnosis with the denaturing gradient gel electrophoresis technique improves diagnostic precision in familial hypercholesterolemia. Circulation 1995b; 91: 1641-1646.
267. Nissen H, Guldberg P, Hansen AB, Petersen NE, Hørder M. Clinically applicable mutation screening in familial hypercholesterolemia. Hum Mutat 1996; 8: 168-177.
268. Nissen H, Hansen AB, Guldberg P, Petersen NE, Hansen TS, Hørder M. Detection and characterization of a novel splice mutation in the LDL receptor intron 12 resulting in two different mutant mRNA variants. Atherosclerosis 1997; 128: 75-83.
269. Nissen H, Day LB, Horder M, Humphries SE, Day INM. Denaturing gradient gel electrophoretic analysis of codons 3456-3553 of the apolipoprotein-B gene in 106 type IIa hyperlipoproteinaemic individuals. Ann Clin Biochem 1998; 35: 137-139.
270. Norman D, Sun X-M, Bourbon M, Knight BL, Naoumova RP, Soutar AK. Characterization of a novel cellular defect in patients with phenotypic homozygous familial hypercholesterolemia. J Clin Invest 1999; 104: 619-628.
271. North CL, Blacklow SC. Evidence that familial hypercholesterolemia mutations of the LDL receptor cause limited local misfolding in an LDL-A module pair. Biochemistry 2000; 39: 13127-13135.
272. O'Dell SD, Humphries SE, Day INM. PCR induction of a Taq1 restriction site at any CpG dinucleotide using two mismatched primers (CpG-PCR). Genome Research 1996; 6: 558-568.
273. O'Dell SD, Wilson DJ, Durrington PN, Humphries SE, Day INM. CpG-PCR combined with sample pooling and mutant enrichment for CpG mutation screening in population studies. Clin Chem 1998; 44: 183-185.
274. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989; 86: 2766-2770.
275. Pak YK, Kanuck MP, Berrios D, Briggs MR, Cooper AD, Ellsworth JL. Activation of LDL receptor gene expression in HepG2 cells by hepatocyte growth factor. J Lipid Res 1996; 37: 985-998.
276. Patel DD, Soutar AK, Knight BL. A mutation and an antibody that affect chemical cross-linking of low-density lipoprotein receptors on human fibroblasts. Biochem J 1993; 289: 569-573.
277. Patterson D, Slack J. Lipid abnormalities in male and female survivors of myocardial infarction and their first-degree relatives. Lancet 1972; i: 393-399.
278. Peeters AV, Kotze MJ, Scholtz CL, De Waal LF, Rubinsztein DC, Coetzee GA, Zuliani G, Streiff R, Liu J, van der Westhuyzen DR. A 3-basepair deletion in repeat 1 of the LDL receptor promoter reduces transcriptional activity in a South African Pedi. J Lipid Res 1998; 39: 1021-1024.
279. Peeters AV, Thiart R, de Villiers, Jensen HK, Van Gaal LF, Kotze MJ. Intronic mutations at splice junctions in the low-density lipoprotein receptor gene. Mol Cell Probes 1999; 13: 257-260.
280. Perhoniemi V, Gylling H, Salmenkivi K. Peripheral atherosclerosis in familial hypercholesterolaemia. J Intern Med 1989; 225: 379-383.
281. Pimstone SN, Gagné SE, Gagné C, Lupien PJ, Gaudet D, Williams RR, Kotze M, Reymer PWA, Defesche JC, Kastelein JJP, Moorjani S, Hayden MR. Mutations in the gene for lipoprotein lipase. A cause for low HDL cholesterol levels in individuals heterozygous for familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15: 1704-1712.
282. Pimstone SN, Defesche JC, Clee SM, Bakker HD, Hayden MR, Kastelein JJP. Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 826-833.
283. Pimstone SN, Sun XM, du Souich C, Frohlich JJ, Hayden MR, Soutar AK. Phenotypic variation in heterozygous familial hypercholesterolemia. A comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. Arterioscler Thromb Vasc Biol 1998; 18: 309-315.
284. Piper J, Orrild L. Essential familial hypercholesterolemia and xanthomatosis. Am J Med 1956; 34-46.
285. Pitkänen OP, Raitakari OT, Niinikoski H, Nuutila P, Iida H, Voipio-Pulkki LM, Härkönen R, Wegelius U, Rönnemaa T, Viikari J, Knuuti J. Coronary flow reserve is impaired in young men with familial hypercholesterolemia. JACC 1996; 28: 1705-1711.
286. Poensgen A. Mittheilung eines seltenen falles von xanthelasma multiplex. Arch Pathol Anat Physiol 1883; 91: 350-370.
287. Pullinger CR, Hennessy LK, Chatterton JE, Liu W, Love JA, Mendel CM, Frost PH, Malloy MJ, Schumaker VN, Kane JP. Familial ligand-defective apolipoprotein B: Identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest 1995; 95: 1225-1234.
288. Raal FJ, Pilcher GJ, Waisberg R, Buthelezi EP, Veller MG, Joffe BI. Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. Am J Cardiol 1999; 83: 1330-1333.
289. Rail SC, Mahley RW. The role of apolipoprotein E genetic variants in lipoprotein disorders. J Int Med 1992; 231: 653-659.
290. Raungaard B, Heath F, Brorholt-Petersen JU, Jensen HK, Færgeman O. Flow cytometric assessment of LDL receptor activity in peripheral blood mononuclear cells compared to gene mutation detection in diagnosis of heterozygous familial hypercholesterolemia. Cytometry 1999; 36: 52-59.
291. Reshef A, Meiner V, Dann EJ, Grenat M, Leitersdorf E. Prenatal diagnosis of familial hypercholesterolemia caused by the "Lebanese" mutation at the low density lipoprotein receptor locus. Hum Genet 1992; 89: 237-239.
292. Reshef A, Nissen H, Triger L, Hansen TS, Eliav O, Schurr D, Safadi R, Gare M, Leitersdorf E. Molecular genetics of familial hypercholesterolemia in Israel. Hum Genet 1996; 98: 581-586.
293. Retterstøl K, Stugaard M, Gørbitz C, Ose L. Results of intensive long-term treatment of familial hypercholesterolemia. Am J Cardiol 1996; 78: 1369-1374.
294. Rodriguez G, Bertolini S, Nobili F, Arrigo A, Masturzo P, Elicio N, Gambaro M, Rosadini G. Regional cerebral blood flow in familial hypercholesterolemia. Stroke 1994; 25: 831-836.
295. Ross R. The pathogenesis of atherosclerosis - An update. N Engl J Med 1986; 314: 488-500.
296. Rubinsztein DC, Jialal I, Leitersdorf E, Coetzee GA, van der Westhuyzen DR. Identification of two new LDL-receptor mutations causing homozygous familial hypercholesterolemia in a South African of Indian origin. Biochim Biophys Acta 1993a; 1182: 75-82.
297. Rubinsztein DC, Raal FJ, Seftel HC, Pilcher G, Coetzee GA, van der Westhuyzen DR. Characterization of six patients who are double heterozygous for familial hypercholesterolemia and familial defective apo B-100. Arteriosclerosis and Thrombosis 1993b; 13: 1076-1081.
298. Rudling M, Norstedt G, Olivecrona H, Reihner E, Gustafsson J, Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci USA 1992; 89: 6983-6987.
299. Rüdiger NS, Heinsvig EM, Hansen FA, Færgeman O, Bolund L, Gregersen N. DNA deletions in the low density lipoprotein (LDL) receptor gene in Danish families with familial hypercholesterolemia. Clin Genet 1991; 39: 451-462.
300. Rødningen OK, Leren TP, Røsby O, Tonstad S, Ose L, Berg K. Haplotype analysis at the low density lipoprotein receptor locus in normal and familial hypercholesterolemia. Clin Genet 1993; 44: 214-220.
301. Rødningen OK, Leren TP. Application of long polymerase chain reaction in the study of the LDL receptor gene. Scand J Clin Lab Invest 1996; 56: 93-96.
302. Rødningen OK, Tonstad S, Ose L, Berg K, Leren TP. Effects of a 9.6-kb deletion of the LDL receptor gene (FH Helsinki) on structure and levels of mRNA. Hum Mutat 1998; 12: 95-102.
303. Rødningen OK, Tonstad S, Medh JD, Chappell DA, Ose L, Leren TP.
304. Rødningen OK, Tonstad S, Saugstad OD, Ose L, Leren TP. Mutant transcripts of the LDL receptor gene: mRNA structure and quantity. Hum Mutat 1999b; 13: 186-196.
305. Sacks FM et al., for the Cholesterol and Recurrent Events Trial Investigators (CARE). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
306. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuschi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-491.
307. Saint-Jore B, Varret M, Dachet C, Rabès JP, Devillers M, Erlich D, Blanchard P, Krempf M, Mathé D, Chanu B, Jacotot B, Farnier M, Bonaïti-Péllié, Junien C, Boileau C. Autosomal dominant type IIa hypercholesterolemia: Evaluation of the respective contributions of LDLR and APOB defects as well as a third major group of defects. Eur J Hum Genet 2000; 8: 621-630.
308. Sakuma N, Iwata S, Ikeuchi R, Ichikawa T, Hibino T, Kamiya Y, Ohte N, Kawaguchi M, Kunimatsu M, Kawahara H, Fujinami T. Coexisting type III hyperlipoproteinemia and familial hypercholesterolemia: A case report. Metabolism 1995; 44: 460-465.
309. Sanchez HB, Yieh L, Osborne TF. Cooperation by sterol regulatory element-binding protein and Sp1 in sterol regulation of low density lipoprotein receptor gene. J Biol Chem 1995; 270: 1161-1169.
310. Sanger F, Nicklen S, Colvson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-5467.
311. Sass C, Giroux LM, Ma Y, Roy M, Lavigne J, Lussier-Cacan S, Davignon J, Minnich A. Evidence for a cholesterol-lowering gene in a French-Canadian kindred with familial hypercholesterolemia. Hum Genet 1995; 96: 21-26.
312. Saxena K, Shipley GG. Structural studies ofdetergent-solubilized and vesicle-reconstituted low-density lipoprotein (LDL) receptor. Biochemistry 1997; 36: 15940-15948.
313. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
314. Schmidt HHJ, Hill S, Makariou EV, Feuerstein IM, Dugi KA, Hoeg JM. Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia. Am J Cardiol 1996; 77: 575-580.
315. Schmidt HHJ, Stuhrmann M, Shamburek R, Schewe CK, Ebhardt M, Zech LA, Büttner C, Wendt M, Beisiegel U, Brewer HB Jr, Manns MP. Delayed low density lipoprotein (LDL) catabolism despite a functional intact LDL-apolipoprotein B particle and LDL-receptor in a subject with clinical homozygous familial hypercholesterolemia. J Clin Endocrinol Metab 1998; 83: 2167-2174.
316. Schmitz G, Brüning T, Kovacs E, Barlage S. Fluorescence flow cytometry of human leukocytes in the detection of LDL receptor defects in the differential diagnosis of hypercholesterolemia. Arteriosclerosis and Thrombosis 1993; 13: 1053-1065.
317. Schneider WJ, Beisiegel U, Goldstein JL, Brown MS. Purification of the low density lipoprotein receptor, an acidic glycoprotein of 164,000 molecular weight. J Biol Chem 1982; 257: 2664-2673.
318. Scholtz CL, Peeters AV, Hoogendijk CF, Thiart R, de Villiers JN, Hillermann R, Liu J, Marais AD, Kotze MJ. Mutation -59c®t in repeat 2 of the LDL receptor promoter: Reduction in transcriptional activity and possible allelic interaction in a South African family with familial hypercholesterolemia. Hum Mol Genet 1999; 8: 2025-2030.
319. Schrott HG, Goldstein JL, Hazzard WR, McGoodwin MM, Motulsky AG. Familial hypercholesterolemia in a large kindred. Evidence for a monogenic mechanism. Ann Intern Med 1972; 76: 711-720.
320. Schuster H, Rauh G, Kormann B, Hepp T, Humphries S, Keller U, Wolfram G, Zöllner N. Familial defective apolipoprotein B-100: Comparison with familial hypercholesterolemia in 18 cases detected in Munich. Arterioscler Thromb 1990; 10: 577-581.
321. Schuster H, Rauh G, Gerl CH, Keller CH, Wolfram G, Zöllner N. Use of DNA haplotype analysis in diagnosis of familial hypercholestaerolemia in 31 German families. J Med Genet 1991; 28: 865-870.
322. Schuster H, Fischer HJ, Keller C, Wolfram G, Zöllner N. Identification of the 408 valine to methionine mutation in the low density lipoprotein receptor in a German family with familial hypercholesterolemia. Hum Genet 1993; 91: 287-289.
323. Schuster H, Keller C, Wolfram G, Zöllner N. Ten LDL receptor mutants explain one third of familial hypercholesterolemia in a German sample. Arterioscler Thromb Vasc Biol 1995a; 15: 2176-2180.
324. Schuster H, Manke C, Fisher J, Keller C, Wolfram G, Zöllner N. Identification of the valine 408 to methionine mutation in the LDL receptor in a Greek patient with homozygous familial hypercholesterolemia. Clin Genet 1995b; 48: 90-92.
325. Scientific Steering Commitee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolemia. BMJ 1991; 303: 893-896.
326. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990; 332: 1494-99.
327. Seftel HC, Baker SG, Sandler MP, Forman MB, Joffe B, Mendelsohn D, Jenkins T, Mieny CJ. A host of hypercholesterolaemic homozygotes in South Africa. BMJ 1980; 281: 633-636.
328. Seftel HC, Baker SG, Jenkins T, Mendelsohn D. Prevalence of familial hypercholesterolemia in Johannesburg Jews. Am J Med Genet 1989; 34: 545-547.
329. Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW, Stone EM. The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. Genomics 1993; 325-332.
330. Sheffield VC, Beck JS, Lirdal A, Nichols B, Cousineau A, Stone EM. Detection of polymorphisms within gene sequences by GC-clamped denaturing gradient gel electrophoresis. Am J Hum Genet 1992; 50: 567-575.
331. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packhard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (WOSCOPS). N Engl J Med 1995; 333: 1301-1307.
332. Sijbrands EJG, Lombardi MP, Westendorp RGJ, Leuven JAG, Meinders AEM, van der Laarse A, Frants RR, Havekes LM, Smelt AHM. Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations. Atherosclerosis 1998; 136: 247-254
333. Sijbrands EJG, Westendorp RGJ, Lombardi MP, Havekes LM, Frants RR, Kastelein JJP, Smelt AHM. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolemia. Atherosclerosis 2000; 149: 421-425.
334. Simard J, Moorjani S, Vohl MC, Couture P, Torres AL, Gagne C, Despres JP, Labrie F, Lupien PJ. Detection of a novel mutation (stop 468) in exon 10 of the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. Hum Mol Genet 1994; 9: 1689-1691.
335. Simon Broome Steering Committee. Steering committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolemia: Implications for clinical management. Atherosclerosis 1999; 142: 105-112.
336. Skovby F, Micic S, Jepsen B, Larsen SO, Hansen B, Tegllund L, Pedersen BN. Screening for familial hypercholesterolaemia by measurement of apolipoproteins in capillary blood. Arch Dis Childhood 1991; 66: 844-847.
337. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 1969; 2: 1380-1382.
338. Slack J. Inheritance of familial hypercholesterolemia. Atheroscler Rev 1979; 5: 35-66.
339. Slimane MN, Pousse H, Maatoug F, Hammami M, Ben-Farhat MH. Phenotypic expression of familial hypercholesterolaemia in central and southern Tunisia. Atherosclerosis 1993; 104: 153-158.
340. Slimane MN, Lestavel S, Sun XM, Maatouk F, Soutar AK, Farhat MH, Clavey V, Benlian P, Hammami M. FH-Souassi: A founder frameshift mutation in exon 10 of the LDL-receptor gene, associated with a mild phenotype in Tunisian families. Atherosclerosis 2001; 154: 557-565.
341. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering in atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet 2001; 357: 577-581.
342. Smith JR, Osborne TF, Goldstein JL, Brown MS. Identification of nucleotides responsible for enhancer activity of sterol regulatory element in low density lipoprotein receptor gene. J Biol Chem 1990; 265: 2306-2310.
343. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest 1994; 93: 50-55.
344. Soria LF, Ludwig EH, Clarke HRG, et al. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 1989; 86: 587-591.
345. Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975; 98: 503-517.
346. Sprecher D, Schaefer EJ, Kent KM et al. Cardiovascular features of homozygous familial hypercholesterolemia: Analysis of 16 patients. Am J Cardiol 1984; 54: 20-30.
347. Sprecher DL, Hoeg JM, Schaefer EJ, Zech LA, Gregg RE, Lakatos E, Brewer HB Jr. The association of LDL receptor activity, LDL cholesterol level, and clinical course in homozygous familial hypercholesterolemia. Metabolism 1985; 34: 294-299.
348. Stein EA, Mieny C, Spitz L, Sadron I, Pettifor J, Heimann KW, Bersohn I, Dinner M. Portacaval shunt in four patients with homozygous hypercholesterolemia. Lancet 1975; 1: 832-835.
349. Stein EA, Illingworth DR, Kwiterovich PO, Liacouras CA, Siimes MA, Jacobson MS, Brewster TG, Hopkins P, Davidson M, Graham K, Arensman F, Knopp RH, DuJovne C, Williams CL, Isaacsohn JL, Jacobsen CA, Laskarzewski PM, Ames S, Gormley GJ. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia. A randomised controlled trial. JAMA 1999; 281: 137-144.
350. Stephan ZF, Yurachek EC. Rapid fluorometric assay og LDL receptor activity by DiI-labeled LDL. J Lipid Res 1993; 34: 325-330.
351. Steyn K, Goldberg YP, Kotze MJ, Steyn M, Swanepoel ASP, Fourie JM, Coetzee GA, van der Westhuyzen DR. Estimation of the prevalence of familial hypercholesterolaemia in a rural Afrikaner community by direct screening for three Afrikaner founder low density lipoprotein receptor gene mutations. Hum Genet 1996; 98: 479-484.
352. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974; XLIX: 476-488.
353. Stopeck AT, Nicholson AC, Mancini FP, Haijar DP. Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells. J Biol Chem 1993; 268: 17489-17494.
354. Streicher R, Kotzska J, Müller-Wieland D, Siemeister G, Munck M, Avci H, Krone W. SREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-1. J Biol Chem 1996; 271: 7128-7133.
355. Sun XM, Patel DD, Webb JC, Knight BL, Fan LM, Cai HJ, Soutar AK. Familial hypercholesterolemia in China. Identification of mutations in the LDL-receptor gene that result in a receptor-negative phenotype. Arterioscler Thromb 1994; 14: 85-94.
356. Sun XM, Patel DD, Bhatnagar D, Knight BL, Soutar AK. Characterization of a sptice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. Arterioscler Thromb 1995a; 15: 219-27.
357. Sun XM, Neuwirth C, Wade DP, Knight BL, Soutar AK. A mutation (T-45C) in the promoter region of the low-density-lipoprotein (LDL)-receptor gene is associated with a mild clinical phenotype in a patient with heterozygous familial hypercholesterolaemia (FH). Hum Mol Genet 1995b; 4: 2125-2129.
358. Sun XM, Patel DD, Knight BL, Soutar AK. Comparison of the genetic defect with LDL-receptor activity in cultured cells from patients with a clinical diagnosis of heterozygous familial hypercholesterolemia. The familial hypercholesterolaemia regression study group. Arterioscler Thromb Vasc Biol 1997; 17: 3092-3101.
359. Sun XM, Patel DD, Knight BL, Soutar AK, The familial hypercholesterolemia regression study group. Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolemia. Atherosclerosis 1998; 36: 175-185.
360. Südhof TC, Goldstein JL, Brown MS, Russel DW. The LDL receptor gene: A mosaic of exons shared with different proteins. Science 1985; 228: 815-822.
361. Südhof TC, van der Westhuyzen DR, Goldstein JL, Brown MS, Russell DW. Three direct repeats and a TATA-like sequence are required for regulated expression of the human low density lipoprotein receptor gene. J Biol Chem 1987; 262: 10773-10779.
362. Takahashi T, Nakano S, Shimazaki Y, Kaneko M, Hirata N, Nakamura T, Matsuzawa Y, Kitamura S, Matsuda H. Long-term appraisal of coronary bypass operations in familial hypercholesterolemia. Ann Thorac Surg 1993; 56: 499-505.
363. Talmud P, Tybjærg-Hansen A, Bhatnagar D, Mbewu A, Miller JP, Durringtion P, Humphries SE. Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia. Atherosclerosis 1991; 89: 137-141.
364. Talmud PJ, Barni N, Kessling AM, Carlsson P, Darnfors C, Bjursell G, Galton D, Wynn V, Kirk H, Hayden MR, Humphries SE. Apolipoprotein B gene variants are involved in the determination of serum cholesterol levels: A study in normo- and hyperlipidaemic individuals. Atherosclerosis 1987; 67: 81-98.
365. Tashiro J, Endo M, Bujo H, Shinomiya M, Morisaki N, Saito Y. New type of the internalization-defective low-density lipoprotein receptor owing to two-nucleotide deletion (2199delCA or 2201delCA) in Japanese patients with familial hypercholesterolemia. Eur J Clin Invest 1998; 28: 712-719.
366. Tatò F, Keller C, Schuster H, Spengel F, Wolfram G, Zöllner N. Relation of lipoprotein(a) to coronary heart disease and duplexsonographic findings of the carotid arteries in heterozygous familial hypercholesterolemia. Atherosclerosis 1993; 101: 69-77.
367. Thannhauser DJ, Magendantz H. The different clinical groups of xanthomatous diseases: A clinical physiological study of 22 cases. Ann Intern Med 1938; 11: 1662-1746.
368. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
369. Thompson GR, Seed M, Nithyananthan S, McCarthy S, Thorogood M. Genotypic and phenotypic variation in familial hypercholesterolemia. Arteriosclerosis 1989; Suppl 19: 175-180.
370. Tolleshaug H, Goldstein JL, Schneider WJ, Brown MS. Posttranslational processing of the LDL receptor and its genetic disruption in familial hypercholesterolemia. Cell 1982; 30: 715-724.
371. Tolleshaug H, Hobfood KK, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: Multiple mutations disrupt transport and processing of a membrane receptor. Cell 1983; 32: 941-951.
372. Tonstad S, Leren TP, Sivertsen M, Ose L. Determinants of lipid levels among children with heterozygous familial hypercholesterolemia in Norway. Arterioscler Thromb Vasc Biol 1995; 15: 1009-1014.
373. Tonstad S, Joakimsen O, Stensland-Bugge E, Leren TP, Ose L, Russell D, Bønaa KH. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol 1996a; 16: 984-991.
374. Tonstad S. Familial hypercholesterolaemia: A pilot study of parents' and children's concerns. Acta Pædiatr 1996b; 85: 1307-1313.
375. Tonstad S, Nøvik TS, Vandvik IH. Psychosocial function during treatment for familial hypercholesterolemia. Pediatrics 1996c; 98: 249-255.
376. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 1996d; 129: 42-49.
377. Tonstad S, Ose L. Colestipol tablets in adolescents with familial hypercholesterolaemia. Acta Pædiatr 1996e; 85: 1080-1082.
378. Top B, van den Boorn N, van der Zee A, Havekes LM, Frants RR. Detection of allele-specific transcripts by the polymerase chain reaction (AST-PCR). Biochem Biophys Res Comm 1991; 178: 1319-1325.
379. Top B, Uitterlinden AG, van der Zee A, Kastelein JJP, Leuven JAG, Havekes LM, Frants RR. Absence of mutations in the promoter region of the low density lipoprotein receptor gene in a large number of familial hypercholesterolaemia patients as revealed by denaturing gradient gel electrophoresis. Hum Genet 1992; 89: 561-565.
380. Torres AL, Moorjani S, Vohl MC, Gagné C, Lamarche B, Brun LD, Lupien PJ, Després JP. Heterozygous familial hypercholesterolemia in children: Low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations. Atherosclerosis 1996; 126: 163-171.
381. Traeger-Synodinos J, Mavroidis N, Kanavakis E, Drogari E, Humphries SE, Day IN, Kattamis C, Matsaniotis N. Analysis of low density lipoprotein receptor gene mutations and microsatellite haplotypes in Greek FH heterozygous children: Six independent ancestors account for 60% of probands. Hum Genet 1998; 102: 343-347.
382. Tricot-Guerber F, Saint-Jore B, Valenti K, Foulon T, Bost M, Hadjian AJ. Identification of a mutation, N543H, in exon 11 of the low-density lipoprotein receptor gene in a French family with familial hypercholesterolemia. Hum Mutat 1995: 87-88.
383. Tsang RC, Fallat RW, Glueck CJ. Cholesterol at birth and age 1. Comparison of normal and hypercholesterolemic neonates. Pediatrics 1974; 4: 458-470.
384. Tybjærg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med 1998; 338: 1577-1584.
385. Tybjærg-Hansen A, Jensen HK, Steffensen R, Schnohr P, Nordestgaard BG. LDL receptor mutations in the population at large: Plasma cholesterol, risk of ischemic heart disease, and comparison with familial defective apolipoprotein B-100. Circulation 1999; (suppl) 100; 18: 1-197. (abstract).
386. Uauy R, Zwiener RJ, Phillips MJ, Petruska ML, Bilheimer DW. Treatment of children with homozygous familial hypercholesterolemia: Safety and efficacy of low-density lipoprotein apheresis. J Pediatr 1992; 120: 892-898.
387. Urdal P, Leren TP, Tonstad S, Lund PK, Ose L. Flow cytometric measurement of low density lipoprotein receptor activity validated by DNA analysis in diagnosing heterozygous familial hypercholesterolemia. Cytometry 1997; 30: 264-268.
388. van Biervliet J-P, Vinaimont N, Caster H, Rosseneu M, Belpaire F. A screening procedure for dyslipoproteinemia in the newborn. Apoprotein quantitation on dried blood spots. Clin Chem Acta 1982; 120: 191-200.
389. van Driel IR, Davis CG, Goldstein JL, Brown MS. Self-association of the low density lipoprotein receptor mediated by the cytoplasmic domain. J Biol Chem 1987; 262: 16127-16134.
390. Varret M, Rabès JP, Collod-Béroud G, Junien C, Boileau C, Béroud C. Software and database for the analysis of mutations in the human LDL receptor gene. Nucleic Acids Research 1997; 25: 172-180.
391. Varret M, Rabès JP, Thiart R, Kotze M, Baron H, Cenarro A, Descamps O, Ebhardt M, Hondelijn JC, Kostner GM, Miyake Y, Pocovi M, Schmidt H, Schuster H, Stuhrmann M, Yamamura T, Junien C, Béroud C, Boileau C. LDLR database (second edition): New additions to the database and the software, and results of the first molecular analysis. Nucleic Acids Research 1998; 26: 248-252.
392. Varret M, Rabès JP, Saint-Jore B, Cenarro A, Marinoni C, Civeira F et al. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am J Hum Genet 1999; 64: 1378-1387.
393. Verhoeye FR, Descamps O, Husson B, Hondekijn JC, Ronveaux-Dupal MF, Lontie JF, Heller FR. An improved method for detction of low density lipoprotein receptor defects in human T lymphocytes. J Lipid Res 1996; 37: 1377-1384.
394. Verschuren WMM, Jacobs DR, Bloemberg BPM, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Nedeljkovic S, Nissinen A, Toshima H. Serum total cholesterol and longterm coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 1995; 274.131-136.
395. Virkola K, Pesonen E, Akerblom HK, Siimes MA. Cholesterol and carotid artery wall in children and adolescents with familial hypercholesterolemia: A controlled study by ultrasound. Acta Paediatr 1997; 86: 1203-1207.
396. Vohl MC, Gaudet D, Moorjani S, Tremblay G, Perron P, Gagné C, Lesiège D, Bergeron J, Lupien PJ, Després JP. Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolemia. Eur J Clin Invest 1997; 27: 366-373.
397. Vuorio AF, Ojala JP, Sarna S, Turtola H, Tikkanen JM, Kontula K. Heterozygous familial hypercholesterolemia: The influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment. J Intern Med 1995; 237: 43-48.
398. Vuorio AF, Paulin L, Turtola H, Kontula K. Deletions of the low density lipoprotein receptor gene underlying familial hypercholesterolaemia: Screening by polymerase chain reaction using pooled DNA and blood samples. Molecular and Cellular Probes 1997a; 11: 65-70.
399. Vuorio AF, Turtola H, Piilahti KM, Repo P, Kanninen T, Kontula K. Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study. Arterioscler Thromb Vasc Biol 1997b; 17: 3127-3138.
400. Vuorio AF, Turtola H, Kontula K. A novel point mutation (Pro84→Ser) of the low density lipoprotein receptor gene in a family with moderate hypercholesterolemia. Clin Genet 1997c; 51: 191-195.
401. Vuorio AF, Turtola H, Kontula K. Neonatal diagnosis of familial hypercholesterolemia in newborns born to a parent with a molecularly defined heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997d; 17: 3332-3337.
402. Walz T, Geisel J, Bodis M, Knapp JP, Herrmann W. Fluorescence-based single-strand conformation polymorphism analysis of mutations by capillary electrophoresis. Electrophoresis 2000; 21: 375-379.
403. Wang XL, Dudman NPB, Wilcken EL. Enzyme-linked immunosorbent assay of apolipoprotein B in blood spotted onto filter paper, suitable for neonatal screening. Clin Chem 1989; 35: 1000-1004.
404. Wang X, Briggs MR, Hua X, Yokoyama C, Goldstein JL, Brown MS. Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. II. Purification and characterization. J Biol Chem 268; 1993: 14497-14504.
405. Wang X, Sato R, Brown MS, Hua X, Goldstein JL. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 1994; 77: 53-62.
406. Webb JC, Sun XM, Patel DD, McCarthy SN, Knight BL, Soutar AK. Characterization of two new point mutations in the low density lipoprotein receptor genes of an English patient with homozygous familial hypercholesterolemia. J Lipid Res 1992; 33: 689-698.
407. Webb JC, Patel DD, Shoulders CC, Knight BL, Soutar AK. Genetic variation at a splicing branch point in intron 9 of the low density lipoprotein (LDL)receptor gene: A rare mutation that disrupts mRNA splicing in a patient with familial hypercholesterolaemia and a common polymorphism. Hum Mol Genet 1996; 5: 1325-1331.
408. Weiss N, Eggersdorfer I, Keller C. Multiplex-PCR-based single-strand conformation polymorphism protocol for simultaneous analysis of up to five fragments of the low-density-lipoprotein receptor gene. Biotechniques 1995; 20: 421-429.
409. Weiss N, Gudnasson V, Ostwald P, Humphries S, Schuster H, Keller C. The usefulness of three biallelic restriction fragment length polymorphisms versus a polymorphic dinucleotide tandem repeat polymorphism at the low-density-lipoprotein receptor gene locus for diagnosis of familial hypercholesterolemia. Dis Markers 1997; 13: 141-151.
410. Weiss N, Binder G, Keller C. Heterozygosity for the missense mutation Ala370*Thr in exon 8 of the low density lipoprotein receptor gene does not cause hypercholesterolemia. Eur J Med Res 1998; 3: 20-24.
411. Wendelhag I, Wiklund O, Wikstrand J. Arterial wall thickness in familial hypercholesterolemia. Ultrasound measurement of intima-media thickness in the common carotid artery. Arterioscler Thromb 1992; 12: 70-77.
412. Wendelhag I, Wiklund O, Wikstrand J. On quantifying plaque size and intima-media thickness in carotid and femoral arteries. Comments on results from a prospective ultrasound study in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996; 16: 843-850.
413. Wenham PR, Haddad L, Panarelli M, Ashby JP, Day INM, Giles PD, Humphries SE, Penney MD, Rae PWH, Walker SW. Simplified detection of a mutation causing familial hypercholesterolemia throughout Britain: Evidence for an origin in a common distant ancestor. Ann Clin Biochem 1998; 35: 226-235.
414. White MB, Carvalho M, Derse D, O'Brien SJ, Dean M. Detecting single base substitutions as heteroduplex polymorphisms. Genomics 1992; 12: 301-306.
415. Whittall R, Gudnason V, Weavind GP, Day LB, Humphries SE, Day INM. Utilities for high throughput use of the single strand conformational polymorphism method: Screening of 791 patients with familial hypercholesterolaemia for mutations in exon 3 of the low density lipoprotein receptor gene. J Med Genet 1995; 32: 509-515.
416. Wierzbicki AS, Lumb PJ, Chik G, Crook MA. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. Int J Clin Pract 1999; 53: 609-611.
417. Wiklund O, Angelin B, Olofsson SO, Eriksson M, Fager G, Berglund L, Bondjers G. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 1990; 335: 1360-1363.
418. Wilkinson CE Jr, Hand EA, Fliegelman MT. Essential familial hypercholesterolemia. Ann Intern Med 1948; 29: 671-686.
419. Williams RR, Hopkins PN, Hunt SC, Wu LL, Hasstedt SJ, Lalouel JM, Ash KO, Stults BM, Kuida H. Population-based frequency of dylipidemia syndromes in coronary-prone families in Utah. Arch Intern Med 1990; 150: 582-588.
420. Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, Hopkins PN. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72: 171-176.
421. Williams RR, Hamilton-Craig I, Kostner GM, Hegele RA, Hayden MR, Pimstone SN, et al. MED PED: An integrated genetic strategy for preventing early deaths. In: Berg K, Boulyjenkow V, Christen Y, eds. Genetic Approaches to Noncommunicable Diseases. Heidelberg: Springer, 1995: 35-45.
422. Wilson DJ, Gahan M, Haddad L, Heath K, Whittall RA, Williams RR, Humphries SE, Day INM. A world wide web site for low-density lipoprotein receptor gene mutations in familial hypercholesterolemia: Sequence-based, tabular, and direct submission data handling. Am J Cardiol 1998; 81: 1509-1511.
423. Wittekoek ME, Pimstone SN, Reymer PWA, Feuth L, Botma GJ, Defesche JC, Prins M, Hayden MR, Kastelein JJP. A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia. Circulation 1998; 97: 729-735.
424. Wittekoek ME, Moll E, Pimstone SN, Trip MD, Lansberg PJ, Defesche JC, van Doormaal JJ, Hayden MR, Kastelein JJP. A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1999; 19: 2708-2713.
425. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of european and other societies on coronary prevention. Eur Heart J 1998; 19: 1434-1503.
426. Wu LL, Hopkins PN, Xin YP, Stephenson SH, Williams RR, Nobe Y, Kajita M, Nakajima T, Emi M. Co-segregation of elevated LDL with a novel mutation (D92K) of the LDL receptor in a kindred with multiple lipoprotein abnormalities. J Hum Genet; 2000: 45; 154-158.
427. Yamamoto A, Kamiya T, Yamamura T, Yokoyama S, Horiguchi Y, Funahashi T, Kawaguchi A, Miyake Y, Beppu S, Ishikamu K, Matsuzawa Y, Takaichi S. Clinical features of familial hypercholesterolemia. Arteriosclerosis 1989; 9 (Suppl 1): 1-66-1-74.
428. Yamamoto T, Davis CG, Brown MS, Scneider WJ, Casey MJ, Goldstein JL, Russell DW. The human LDL receptor: A cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 1984; 39: 27-38.
429. Yanagi K, Yamashita S, Kihara S, Nakamura T, Nozaki S, Nagai Y, Funahashi I, Kameda-Takemura K, Ueyama Y, Jian S, Kubo M, Tokunaga K, Matsuzawa Y. Characteristics of coronary artery disease and lipoprotein abnormalities in patients with heterozygous familial hypercholesterolemia associated with diabetes mellitus or impaired glucose tolerance. Atherosclerosis 1997; 132: 43-51.
430. Yokoyama I, Ohtake T, Momomura S, Nishikawa J, Sasaki Y, Omata M. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation 1996; 94: 3232-3238.
431. Yokoyama C, Wang X, Briggs MR, Admon A, Wu J, Hua X, Goldstein JL, Brown MS. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 1993; 75: 187-197.
432. Zuliani G, Vigna GB, Corsini A, Maioli M, Romagnoni F, Fellin R. Severe hypercholesterolaemia: Unusual inheritance in an Italian pedigree. Eur J Clin Invest 1995; 25: 322-331.
433. Zuliani G, Arca M, Signore A, Bader G, Fazio S, Chianelli M, Bellosta S, Campagna F, Montali A, Maioli M, Pacifico A, Ricci G, Fellin R. Characterization of a new form of inherited hypercholesterolemia. Familial recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 1999; 19: 802-809.
434. Zwiener RJ, Uauy R, Petruska ML, Huet BA. Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia. J Pediatr 1995; 126: 728-735.